Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Mar 11 | 2024Lexicon Q4 ’23 Earnings; Lexicon to Resubmit Sota T1DM NDA; MannKind INHALE-3 Initial Results; Praluent Receives Pediatric HeFH FDA ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Mar 09 | 2024ATTD 2024 Key Press Releases Day 4 (March 9)Purchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other Mar 08 | 2024ATTD 2024 Key Press Releases Day 2 & 3 (March 7 & 8); Xeris Q4 ’23 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other Mar 07 | 2024Novo Nordisk 2024 Capital Markets Day Highlights and AnalysisPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Mar 06 | 2024ATTD 2024 Key Press Releases Day 1 (March 6)Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Mar 06 | 2024FENIX Analysis: Viking Suitors - Who is Going to Claim Their Piece of the Obesity Pie?Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Mar 06 | 2024FLOW Topline Results; EMA Accepts Madrigal’s Resmetirom MAA; Lilly Saving Card Outage; Alnylam and Roche Report KARDIA-2 Topline Results; Dexcom, Insulet, and MannKind to Present at ATTD 2024Purchase Blast
$599
Posted in: Other Mar 04 | 2024Akero Wins with Ph2b HARMONY MASH Results; Lilly Initiates Ph3 Lp(a) CVOT; vTv Submits T1DM Study Protocol to FDAPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Feb 29 | 2024Senseonics, Akero, Amarin Q4 '23 Earnings; Viking Commences $550M Public Offering; Pfizer and Regor Initiate Oral GLP-1RA Studies; Virta Published GLP-1RA Discontinuation ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Feb 28 | 2024Abbott and Dexcom Ads Observed; Madrigal, Esperion, Mannkind, Viatris Q4 ’23 Earnings; AZ Terminates Rights to RoxadustatPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Feb 27 | 2024Viking Ph2 Data Impresses; Zealand Q4 ’23 Earnings Update; Know Labs Advances Non-Invasive CGM; Glucotrack Selects ManufacturerPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 26 | 2024BI/Zealand Win with Positive Ph2 MASH Data; Novo Partners with Neomorph for Drug Discovery; Modular Medical Raises $10MPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 23 | 2024Insulet Q4 ’23 Earnings; SELECT CHMP Decision in April?; Silence Achieves $10M Milestone Payment from AZPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Feb 22 | 2024FDA Warns Against Glucose-Sensing Smartwatches; Novo Nordisk Foundation Invests in CVRM Diagnosis and Prevention; AZ Initiates Dapa/Zibotentan Ph2b Study; Tandem Initiates an Extended Infusion Set StudyPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Feb 21 | 2024Tandem Q4 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other Feb 21 | 2024Novo Initiates Icosema COMBINE 4 Ph3 Trial; Eccogene Initiates Ph1 Oral GLP-1RA Study; Ionis and Teladoc Q4 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Feb 20 | 2024Lilly Initiates Retatrutide T2DM Pivotal Program; Medtronic CY Q4 ’23 (FY Q3 ’24) Earnings; February CHMP Agenda; Inventiva Pauses Ph3 MASH Trial; Better Therapeutics Receives BDD for MASHPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i Feb 15 | 2024Lilly Launches Mounjaro in the UK; Mannkind Completes INHALE-1 Enrollment; Diamyd Receives Fast Track Designation in T1DM; Alnylam Q4 ’23 EarningsPurchase Blast